CONFERENCES 7-8 February 2017 * COPENHAGEN

NEWS, KNOWLEDGE, EXPERIENCE & INSPIRATION

eCTD
– a practical perspective

eCTD v4.0 and Beyond
eSUBMISSION ROADMAP
– EU & US
TRANSITION FROM PAPER TO eCTD
– change management
AGENCY RESPONSE
OUTSOURCING OF eCTD
GLOBAL eCTD

SPEAKERS REPRESENTING:
Danish Medicines Agency (DK) * Finnish Medicines Agency (FI) * Medicines and Healthcare Products Regulatory Agency (UK) * Boehringer Ingelheim (D) * Novo Nordisk (DK) * Hansa Medical (SE) Symphogen (US) * Ferring Pharmaceuticals (DK) * Bridge Regulatory Affairs (US) * NNIT (DK)
Speakers

AUTHORITIES
Special Adviser
Mickel Hedemand
Danish Medicines Agency (DK)

Director, Information Resources
Juha-Pekka Nenonen
Finnish Medicines Agency (FI)

Delivery Manager
Rachel Hyde
Medicines and Healthcare Products Regulatory Agency (UK)

INDUSTRY
Head of Global Submission Services
Dr. Melanie Ruppel
Boehringer Ingelheim (D)

RA Senior Project Manager
Helle Ainsworth
Novo Nordisk A/S (DK)

Senior Project Manager
Principal Scientist
Åsa Schiött
Hansa Medical AB (SE)

Head of Regulatory Affairs
Associate Director
Meghan Brown
Global Regulatory Affairs, Symphogen (US)

Regulatory Affairs Manager
Lise Laurbjerg Nielsen
Ferring Pharmaceuticals A/S (DK)

ADVISORS
CEO Bridgette Kunst
Bridge Regulatory Affairs, LLC (US)

Global Regulatory Affairs Lead Managing Consultant
Ph.D. Niels Buch Leander
NNIT A/S (DK)

Principal Consultant
Mette Bugge
NNIT A/S (DK)

The conference has been developed in cooperation with

IWA Consulting Aps

Partners

medicon valley alliance

COBIS
Copenhagen Bio Science Park
eCTD – a practical perspective

08.30-09.00 Registration
   Morning Coffee

09.00-09.05 Welcome
   Relevent ApS

09.05-09.10 Chairman's Opening Remarks
   Conference Chair: Managing Partner, Head R&M Development
   Lillian Rejkjær, IWA Consulting ApS (DK)

09.10-09.40 eSUBMISSION ROADMAP
   eCTD v4.0 and Beyond
   – Strategies to Deal with the Future of eCTD
   Recently certain regions have started to introduce the RPS (Regulatory Product Submission) standard for the next generation eCTD (v4.0) into their existing current specifications. How transformative is this upcoming version of eCTD?
   • New perspectives and challenges with eCTD v4.0
   • The regulators' intention with eCTD v4.0
   • eCTD v4.0 and its relations to other Regulatory Affairs challenges such as ISO IDMP
   • Preparing for eCTD v4.0 and its context
   Global Regulatory Affairs Lead, Managing Consultant, Ph.D. Niels Buch Leander, NNIT A/S (DK)

09.40-09.50 BREAK

09.50-10.20 eSubmission Roadmap – EU & EU Countries
   • EU – status, when is it mandatory and where?
   Special Adviser Mickel Hedemand, Danish Medicines Agency (DK)

10.20-11.00 eSubmission Roadmap – EU & EU Countries
   • What is the impact on the industry?
   Head of Global Submission Services, Dr. Melanie Ruppel, Boehringer Ingelheim (DE)

11.00-11.15 BREAK

11.15-12.00 eSubmission Roadmap – US
   • FDA Forms and electronic signature
   • Electronic submission gateway
   CEO Bridgette Kunst, Bridge Regulatory Affairs, LLC (US)

12.00-13.00 LUNCH

13.00-13.40 CESP/EMA Gateway and Future Repositories
   • What is coming – where are we heading?
   • PSUR repository
   • Common Repository
   Director, Information Resources Juha-Pekka Nenonen, Finnish Medicines Agency (FI)

13.40-13.50 BREAK

13.50-14.30 CHANGING ENVIRONMENT
   New EMA Policy On Transparency (0070) & eCTD Submission (Redacted Clinical Data)
   • What will be closed off from the public (also by eCTD)?
   • Publication of clinical reports
   RA Senior Project Manager Helle Ainsworth, Novo Nordisk A/S (DK)

14.30-14.45 BREAK

14.45-15.30 Automation in Regulatory Documentation
   • Options for automation of creation and maintenance of regulatory documentation
   • How to automate the harmonization of regulatory eCTD documents with data-based submissions such as IDMP and CTA
   Principal Consultant Mette Bugge, NNIT A/S (DK)

15.30-15.40 BREAK

15.40-16.25 eAF - Data Reuse in other Connections (e.g. IDMP)
   • Status
   • eCTD impact on application form (EU & US)
   • Application form – IDMP
   • How do the authorities use the data?
   • The ability of the authorities to draw data from eAF
   Special Adviser Mickel Hedemand, Danish Medicines Agency (DK)
   CEO Bridgette Kunst, Bridge Regulatory Affairs, LLC (US)

16.25-16.30 Chairman's Closing Remarks

16.30 End of Conference Day
### PROGRAM  February 8, 2017

#### TRANSITION FROM PAPER TO eCTD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-09.00</td>
<td>Registration  Morning Coffee</td>
</tr>
</tbody>
</table>
| 09.00-09.40 | Change Management  • How to engage the organisation?  
                        RA Senior Project Manager **Helle Ainsworth**, Novo Nordisk A/S (DK) |
| 09.40-09.50 | BREAK                                      |
| 09.50-10.25 | Applications in eCTD – Transition from Paper to eCTD  
                        • What have we done, which considerations, experiences?  
                        • How has the company been prepared for the future of only eCTD?  
                        TBA                                      |
| 10.25-11.00 | Submission of First eCTD  
                        • Plan your documentation - when you start, start right  
                        Senior Project Manager, Principal Scientist **Åsa Schiött**, Hansa Medical AB (SE) |
| 11.00-11.15 | BREAK                                      |

#### AGENCY PERSPECTIVE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11.15-12.00 | Agency Response  
                        • Receipt, registration and handling of an eCTD (clear references, file naming)  
                        • Typical eCTD/validation issues/errors from an agency point of view  
                        Delivery Manager **Rachel Hyde**, Medicines and Healthcare Products Regulatory Agency (UK) |
| 12.00-13.00 | LUNCH                                      |

#### OUTSOURCING OF eCTD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13.00-13.40 | Outsourcing of eCTD – Smaller Companies  
                        • What to be aware of?  
                        Head of Regulatory Affairs, Associate Director **Meghan Brown**,  
                        Global Regulatory Affairs, Symphogen (US) |
| 13.40-14.20 | Outsourcing of eCTD – Larger Companies  
                        • What to be aware of?  
                        • In-house consultants for project specific compiling?  
                        • Compiling at a Consultancy company?  
                        TBA                                      |
| 14.20-14.35 | BREAK                                      |

#### GLOBAL eCTD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14.35-15.15 | Comparison of eCTD by Regions  
                        Implementation of eCTD is evolving with different speeds and frequencies in different Regions. For global pharmaceutical companies this development is a business processes challenge in the context of submission, publishing and validation.  
                        • Which are the most important differences?  
                        • How to overcome the challenge?  
                        TBA                                      |
| 15.15-15.25 | BREAK                                      |
| 15.25-16.05 | Global Submissions  
                        Regulatory Affairs Manager **Lise Laurbjerg Nielsen**, Ferring Pharmaceuticals A/S (DK) |
| 16.05-16.15 | Chairman's Closing Remarks                                      |
| 16.15   | End of Conference                                      |
PRACTIAL ISSUES

WHERE
COBIS - Copenhagen Bio Science Park, Ole Maaløes Vej 3, DK-2200 Copenhagen N,
phone +45 70 70 29 80.

WHEN
Tuesday 7 February and Wednesday 8 February 2017.

WHAT
| Registration before Jan. 6 2017 | DKK 6.995 (excl. VAT) |
| Registration from Jan. 6 2017 | DKK 7.495,- (excl. VAT) |

The registration fee includes conference delegate material, refreshments and lunches.

Feel free to contact us, if one or more of your colleagues are interested too.

Members of MVA and COBIS get a discount, please remember to inform us about your membership when you register.

HOW
Registration on info@relevent.dk or +45 28305445/ +45 41951429.

Cancellations must be in writing on info@relevent.dk and will be subject to a cancellation fee.
Cancellation fees before January 24 2017 - 10% of registration fee.
Cancellation fees before February 5, 2017 - 50% of registration fee.
Cancellation fees from February 5, 2017 – no refund, thus 100% of registration fee.

To avoid cancellation fees – you may transfer your registration to a colleague.
Please inform Relevent prior to the conference on info@relevent.dk.